Clinical trials located in

Cuneo

Cuneo city is located in Italy. Currently, 8 clinical trials are being conducted in this city.

Cuneo, nestled in the Piedmont region of Italy, is a city rich in history and natural beauty. Founded in 1198, it is surrounded by the majestic Alps, offering stunning landscapes. The city’s layout is unique, resembling a wedge or “cuneo” in Italian, from which its name derives. Cuneo boasts an impressive medieval old town, characterized by arcaded streets and historic buildings. The annual “Fiera del Marrone,” celebrating the local chestnut harvest, highlights Cuneo’s deep-rooted culinary traditions. Additionally, the city serves as a gateway to the renowned Langhe wine region, further cementing its cultural significance.

  • CT-EU-00116695

    Study on combining two drugs – Fianlimab and Cemiplimab in patients with previously untreated melanoma

    This study examines two drugs, fianlimab and cemiplimab, given together for the treatment of melanoma. The main goal is to see how effective this drug combination is in treating melanoma compared with pembrolizumab, which is already approved for the treatment of melanoma in adults. The study will also look at whether there are any differences in the effects of these experimental drugs in adolescents and adults.

    Scientists also want to learn about other key issues: what side effects may occur from taking these experimental drugs, how much of the drugs enter the bloodstream over time, and whether the body produces antibodies to the drugs that could make them less effective or cause side effects. They will also check whether taking medications improves patients’ quality of life. Fianlimab and cemiplimab will be administered by intravenous infusion, and pembrolizumab will be administered by intravenous infusion.

    • placebo
    • Fianlimab
    • Cemiplimab
    • Pembrolizumab
  • Testing ravulizumab for transplant-related blood complications

    The study is examining a drug called ravulizumab used in adults and teenagers with a blood vessel disease called thrombotic microangiopathy (TMA) after a bone marrow transplant. Sometimes, new cells growing after a bone marrow transplant can cause problems in the blood vessels leading to TMA. So this study will investigate whether ravulizumab can help in this situation. In the first stage, each participant will receive the drug to determine the best dose. In the second phase, some will receive ravulizumab and best supportive care, while others will receive placebo and best supportive care. After 26 weeks of treatment, doctors will continue to monitor and record the patients’ health for another 26 weeks. Special blood tests will be done to check if the medicine is working.

    • Ravulizumab
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Evaluating treatment strategies for small-cell lung cancer: A clinical trial with lurbinectedin, irinotecan, and topotecan

    This is a large test the researchers are running to help people with a certain type of lung cancer (called Small-cell Lung Cancer) that’s come back after they’ve had one type of treatment that contains platinum. The researchers are using three different ways of giving medicine to see which is best. The first way is to give only lurbinectedin. The second way is to give lurbinectedin and irinotecan together. The third way is to let the doctor decide to use topotecan or irinotecan alone. People’s selection to these groups will be by chance.

    • Irinotecan
    • topotecan
    • Lurbinectedin
  • Study on dersimelagon’s effect on sunlight exposure symptoms

    This clinical trial aims to explore the effectiveness of a new medication, MT-7117 (dersimelagon), in reducing symptoms related to sun exposure in individuals with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP). The study enrolls 150 participants, both adults and adolescents, who have been diagnosed with EPP or XLP. Participants are randomly assigned to either receive dersimelagon or a placebo, in a double-blind format, ensuring neither the participants nor the study staff know who receives the actual medication or the placebo. The primary focus of the study is to observe the changes in the time it takes for symptoms like burning, tingling, itching, or stinging to appear after sun exposure. Secondary outcomes include the patient’s impression of change and the number of sunlight-induced pain events. This research could potentially offer new relief options for those affected by these rare sunlight sensitivity conditions.

    • Dersimelagon
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Italy:

.